Tradestie Institutional Equity Comparison Engine

BOLD vs AVTX โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

BOLD Overall Edge

BOLD Captures Institutional Edge (3โ€“0 Pillars ยท 4โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Boundless Bio, Inc. Common Stock (BOLD) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, BOLD trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus AVTX at N/M Forward P/E and -161962.7% operating margin (-69.3% YoY). In options structure, BOLD sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against AVTX sits in BREAKDOWN (15th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
BOLD N/M vs AVTX N/M Fwd P/E
Growth & Margin Winner BOLD
Op Margin 0.0% vs -161962.7% ยท YoY +0.0% vs -69.3%
Momentum & Technical Winner BOLD
1Y +101.7% vs -61.6% ยท 52W Pos 62% vs 1%
Options & Structure Winner BOLD
UNCLASSIFIED (N/A IV) vs BREAKDOWN (15th %ile IV)
BOLD NASDAQ
Boundless Bio, Inc. Common Stock
Pharmaceutical Preparations
$2.32
-2.52% 1D
Market Cap $56.2M
1M Return -4.92%
1Y Return +101.74%
Forward P/E N/M
Unified AI Score
36.8 / 100 SELL
Tech 25.0 Fund 50.0 Flow 50.0 Mom 60.0
AVTX NASDAQ
Avalo Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$6.76
+0.15% 1D
Market Cap $390.3M
1M Return -9.26%
1Y Return -61.57%
Forward P/E N/M
Unified AI Score
45.6 / 100 HOLD
Tech 39.0 Fund 61.0 Flow 68.0 Mom 68.9

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: BOLD +101.74% AVTX -61.57% Spread: +163.31 pp (BOLD Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
BOLD TTM Op. Margin: 0.0% AVTX TTM Op. Margin: -161962.7%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BOLD vs AVTX. Trailing 12-month operating profitability (BOLD 0.0% vs AVTX -161962.7%) and valuation multiples (BOLD N/M vs AVTX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: BOLD (4) vs AVTX (3)
Institutional Metric BOLD AVTX Criterion Row Winner
Market Capitalization Scale $56.2M $390.3M Larger Scale AVTX
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% -69.3% Higher Growth BOLD
Operating Margin (TTM) Profitability 0.0% -161962.7% Higher Margin BOLD
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -64.6% -33.6% Higher ROE AVTX
52-Week Range Position Momentum 62% ($1โ€“$3) 1% ($7โ€“$24) Stronger Trend BOLD
Beta / 30D Volatility Risk Regime -0.08ฮฒ ยท 28% Vol 1.54ฮฒ ยท 94% Vol Lower Realized Risk BOLD
Unified Institutional Score Composite Signal 36.8 / 100 (SELL) 45.6 / 100 (HOLD) Higher Composite AVTX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full BOLD vs AVTX Buy Guide
BOLD UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live BOLD Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
AVTX BREAKDOWN
137d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 15th %ile
IV Regime Compressed (<25th %ile)
Live AVTX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither BOLD nor AVTX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.